Rituximab Adult FRNS/SDNS (2025) — Trial Summary
Rituximab Adult FRNS/SDNS (2025): Multicenter, double-blind, randomized, placebo-controlled trial at 13 centers in Japan of intravenous rituximab 375 mg/m² versus placebo at weeks 1, 2, and 25 in adults with frequently relapsing or steroid-dependent nephrotic syndrome who were in remission (urine pr
References
- Isaka Y, Sakaguchi Y, Shinzawa M, et al. Rituximab for Relapsing Nephrotic Syndrome in Adults: A Randomized Clinical Trial. JAMA. 2025;334(22):2011-2019. jRCT2051200045; UMIN000041475.